Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Fosun Pharma outlicensed XH-S004 to Expedition Therapeutics for $120M upfront and milestone payment. Remegen’s drug candidate met primary endpoint in Phase 3 trial for Sjögren's syndrome in China.</li>
<li>Astellas Pharma announced positive topline results from the Phase 3 trial evaluating Padcev in bladder cancer. Daewoong Pharmaceutical announced positive result for their self-developed semaglutide microneedle patch.</li>
<li>Zydus Lifesciences received FDA approval for chest pain drug Diltiazem Hydrochloride tablets. Lupin has partnered with Sandoz to market and commercialize Lupin’s biosimilar ranibizumab across multiple regions.</li>
</ul>


Fosun Pharma outlicensed XH-S004 to Expedition Therapeutics for $120M upfront and milestone payment. Remegen’s drug candidate met primary endpoint in Phase 3 trial for Sjögren's syndrome in China.
Astellas Pharma announced positive topline results from the Phase 3 trial evaluating Padcev in bladder cancer. Daewoong Pharmaceutical announced positive result for their self-developed semaglutide microneedle patch.
Zydus Lifesciences received FDA approval for chest pain drug Diltiazem Hydrochloride tablets. Lupin has partnered with Sandoz to market and commercialize Lupin’s biosimilar ranibizumab across multiple regions.


APAC Healthcare Weekly (Aug 17) – Fosun Pharma, Remegen, Astellas, Daewoong Pharma, Zydus, Lupin

<ul>
<li>Hansoh Pharmaceutical announced that a new indication of Xinyue has been included in the Priority Review. Astellas Pharma announced positive update from the Phase 3 EV-302 clinical trial.</li>
<li>CSL has received EU approval for HAE drug, Andemry. Imugene announce more positive results from its Phase 1b trial of azer-cel, an allogenic therapy in relapsed/refractory diffuse large B-cell lymphoma.</li>
<li>LigaChem Bio signed technology transfer agreement for a new anticancer target antibody for the development of ADC candidates with Daan Biotherapeutics. Lupin received FDA approval for generic Atrovent Nasal Spray.</li>
</ul>


Hansoh Pharmaceutical announced that a new indication of Xinyue has been included in the Priority Review. Astellas Pharma announced positive update from the Phase 3 EV-302 clinical trial.
CSL has received EU approval for HAE drug, Andemry. Imugene announce more positive results from its Phase 1b trial of azer-cel, an allogenic therapy in relapsed/refractory diffuse large B-cell lymphoma.
LigaChem Bio signed technology transfer agreement for a new anticancer target antibody for the development of ADC candidates with Daan Biotherapeutics. Lupin received FDA approval for generic Atrovent Nasal Spray.


APAC Healthcare Weekly (Feb 16)- Hansoh Pharma, Astellas Pharma, CSL, Imugene, LigaChem Bio, Lupin

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>I tally 23- mostly firm, mostly Asia-Pac - arb transactions currently being discussed and analysed on Smartkarma. Those arbs metrics and upcoming events are detailed below.</li>
<li>Two new deal was discussed on Smartkarma this week: <a href="https://www.smartkarma.com/entities/regis-resources-ltd" target="_blank" data-smartkarma-citation="entities:20106:1" rel="noopener">Regis Resources (RRL AU)</a> / <a href="https://www.smartkarma.com/entities/vault-minerals-ltd" target="_blank" data-smartkarma-citation="entities:46317:1" rel="noopener">Vault Minerals Ltd (VAU AU)</a>'s merger, and <a href="https://www.smartkarma.com/entities/atlantic-lithium-ltd" target="_blank" data-smartkarma-citation="entities:40322:1" rel="noopener">Atlantic Lithium (A11 AU)</a>'s Scheme.</li>
<li>Key updates/news also took place on: <a href="https://www.smartkarma.com/entities/healius-ltd-6d4d947d-ad32-4aea-b2d8-265f5768b55e" target="_blank" data-smartkarma-citation="entities:14208:1" rel="noopener">Healius (HLS AU)</a>, <a href="https://www.smartkarma.com/entities/atlas-arteria-ltd" target="_blank" data-smartkarma-citation="entities:14430:1" rel="noopener">Atlas Arteria (ALX AU)</a>, <a href="https://www.smartkarma.com/entities/humm-group" target="_blank" data-smartkarma-citation="entities:35366:1" rel="noopener">Humm Group (HUM AU)</a>, <a href="https://www.smartkarma.com/entities/guocoland-malaysia-bhd" target="_blank" data-smartkarma-citation="entities:16496:1" rel="noopener">Guocoland Malaysia (GUOL MK)</a>, and <a href="https://www.smartkarma.com/entities/china-shengmu-organic-milk" target="_blank" data-smartkarma-citation="entities:12714:1" rel="noopener">China Shengmu Organic Milk (1432 HK)</a>.</li>
</ul>


I tally 23- mostly firm, mostly Asia-Pac - arb transactions currently being discussed and analysed on Smartkarma. Those arbs metrics and upcoming events are detailed below.
Two new deal was discussed on Smartkarma this week: Regis Resources (RRL AU) / Vault Minerals Ltd (VAU AU)'s merger, and Atlantic Lithium (A11 AU)'s Scheme.
Key updates/news also took place on: Healius (HLS AU), Atlas Arteria (ALX AU), Humm Group (HUM AU), Guocoland Malaysia (GUOL MK), and China Shengmu Organic Milk (1432 HK).


Asia-Pac M&A Weekly Wrap: Regis/Vault, Atlantic Lithium, Atlas Arteria, Humm, China Shengmu

<ul>
<li>Despite <a href="https://www.smartkarma.com/entities/mitsubishi-pencil-co-ltd" target="_blank" data-smartkarma-citation="entities:3719:1" rel="noopener">Mitsubishi Pencil (7976 JP)</a>'s shoicking governance, unless you are willing to fight it in court (and probably lose), the right thing to do here is buy on weakness.</li>
<li>Assuming <a href="https://www.smartkarma.com/entities/china-resources-power-holdings-co-ltd" target="_blank" data-smartkarma-citation="entities:5385:1" rel="noopener">China Resources Power (836 HK)</a>'s A-share listing of its renewable energy unit unfolds,  there remains material upside here. </li>
<li>Perhaps <a href="https://www.smartkarma.com/entities/ck-hutchison-holdings-ltd" target="_blank" data-smartkarma-citation="entities:132:1" rel="noopener">CK Hutchison (1 HK)</a> now views the (required) high forward spending on VodafoneThree to secure this "golden ticket" no longer makes commercial sense</li>
</ul>


Despite Mitsubishi Pencil (7976 JP)'s shoicking governance, unless you are willing to fight it in court (and probably lose), the right thing to do here is buy on weakness.
Assuming China Resources Power (836 HK)'s A-share listing of its renewable energy unit unfolds,  there remains material upside here. 
Perhaps CK Hutchison (1 HK) now views the (required) high forward spending on VodafoneThree to secure this "golden ticket" no longer makes commercial sense


Last Week In Event SPACE: Mitsubishi Pencil, China Resources Power, CK Hutchison, Guoco

<ul>
<li>S&amp;P/ASX 200 gained 14% during 2021, higher than other developed markets in Asia-Pacific. Many healthcare stocks remained resilient to the resurgence of the COVID-19 pandemic and outperformed the broader market.</li>
<li>Despite the recent surge, Australia’s total infection and deaths numbers are lower than many comparable countries. Australian government has so far ruled out the possibility of lock down.</li>
<li>In this insight, we have discussed five high growth ideas, with attractive business model and strong growth opportunities. Despite Omicron, these stocks are expected to continue their strong performance.</li>
</ul>


S&amp;P/ASX 200 gained 14% during 2021, higher than other developed markets in Asia-Pacific. Many healthcare stocks remained resilient to the resurgence of the COVID-19 pandemic and outperformed the broader market.
Despite the recent surge, Australia’s total infection and deaths numbers are lower than many comparable countries. Australian government has so far ruled out the possibility of lock down.
In this insight, we have discussed five high growth ideas, with attractive business model and strong growth opportunities. Despite Omicron, these stocks are expected to continue their strong performance.


Australian Healthcare: High Growth Ideas for 2022

Australia

Healius Limited provides health care services. The Company offers diagnostic imaging, pathology, acute and chronic disease treatment, dental and eye care, and in vitro fertilisation services. Healius serves patients in Australia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Healius (HLS AU)

APAC Healthcare Weekly (Aug 17) – Fosun Pharma, Remegen, Astellas, Daewoong Pharma, Zydus, Lupin

Astellas, Remegen, and Daewoong Pharma announced positive trial results for their respective drug candidates. Fosun Pharma stuck outlicensing deal....

Tina Banerjee

APAC Healthcare Weekly (Feb 16)- Hansoh Pharma, Astellas Pharma, CSL, Imugene, LigaChem Bio, Lupin

APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...

Tina Banerjee

Asia-Pac M&A Weekly Wrap: Regis/Vault, Atlantic Lithium, Atlas Arteria, Humm, China Shengmu

This insight provides a summary of gross/annualised spreads (on deals discussed on Smartkarma) across Asia-Pacific as at the last trading date, and...

David Blennerhassett

Last Week In Event SPACE: Mitsubishi Pencil, China Resources Power, CK Hutchison, Guoco

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

David Blennerhassett

Australian Healthcare: High Growth Ideas for 2022

Australian equity market is expected to continue its superior performance in 2022. This insight has highlighted five high growth healthcare ideas,...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)